Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Genome-wide Association Studies-GWAS01:11

Genome-wide Association Studies-GWAS

Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
Comparing Copy Number Variations and SNPs02:26

Comparing Copy Number Variations and SNPs

Sequencing of the human genome has opened up several best-kept secrets of the genome. Scientists have identified thousands of genome variations that exist within a population. These variations can be a single nucleotide or a larger chromosomal variation.
Copy number variations or CNVs are the structural variations that cover more than 1kb of DNA sequence. The single nucleotide polymorphism (SNP), on the other hand, is a single nucleotide change or a point mutation that is found in more than 1%...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Single Nucleotide Polymorphisms-SNPs01:05

Single Nucleotide Polymorphisms-SNPs

A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Home CPAP/NIV in pediatric patients: which disorders?

Sleep medicine·2026
Same author

A gut microbiome-kidney-heart axis predictive of future cardiovascular diseases.

Nature communications·2026
Same author

Meta-analysis of genome-wide association studies of food allergy and IgE sensitization.

The Journal of allergy and clinical immunology·2026
Same author

Functional assessment of a convergent gene network underlying allergic diseases and IgE.

The Journal of allergy and clinical immunology·2026
Same author

Unraveling shared genetics across asthma subtypes and 81 asthma-related traits.

The Journal of allergy and clinical immunology·2025
Same author

Genetic characterization of preschool wheeze phenotypes.

The Journal of allergy and clinical immunology·2025

Related Experiment Video

Updated: Jul 4, 2026

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry
05:53

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry

Published on: June 21, 2018

Replication of association between ADAM33 polymorphisms and psoriasis.

Valérie Siroux1, Emmanuelle Bouzigon, Marie-Hélène Dizier

  • 1Inserm, U823, Centre de Recherche Albert Bonniot, Epidémiologie des cancers et des affections graves, La Tronche, France. valerie.siroux@ujf-grenoble.fr

Plos One
|June 19, 2008
PubMed
Summary

Genetic variants in ADAM33 are associated with psoriasis, replicating previous findings. This study identifies specific ADAM33 SNPs linked to psoriasis and early-onset forms, suggesting a pleiotropic role in immune-mediated diseases like asthma and psoriasis.

Related Experiment Videos

Last Updated: Jul 4, 2026

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry
05:53

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry

Published on: June 21, 2018

Area of Science:

  • Genetics
  • Dermatology
  • Immunology

Background:

  • Polymorphisms in ADAM33, a gene previously linked to asthma, have been suggested to associate with psoriasis.
  • No prior studies have replicated this association between ADAM33 and psoriasis.

Purpose of the Study:

  • To replicate the association between ADAM33 gene polymorphisms and psoriasis in a French population.
  • To investigate the association of ADAM33 variants with early-onset psoriasis.
  • To explore the potential independent effects of ADAM33 and PSORS1 on psoriasis.

Main Methods:

  • Genotyping of 9 SNPs in ADAM33 and 11 SNPs in PSORS1 in 2002 individuals from the EGEA study.
  • Association analysis using GEE regression and a likelihood-based method (LAMP).
  • Psoriasis assessment via interviewer-administered questionnaire; early-onset psoriasis defined as onset before age 40.

Main Results:

  • The rs512625 SNP in ADAM33 was significantly associated with psoriasis (p = 0.01).
  • The rs628977 SNP in ADAM33 showed a significant association with early-onset psoriasis (p = 0.01).
  • These associations remained significant after adjusting for age, sex, asthma, and PSORS1 SNPs, suggesting independent effects.

Conclusions:

  • This study provides the first replication of the association between ADAM33 genetic variants and psoriasis.
  • Specific ADAM33 SNPs are linked to psoriasis and early-onset psoriasis, supporting a pleiotropic role for ADAM33.
  • The findings contribute to understanding the genetic basis of common immune-mediated diseases like asthma and psoriasis.